Tradestie Institutional Equity Comparison Engine

DSGN vs DAWN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DAWN Overall Edge

DAWN Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Day One Biopharmaceuticals, Inc. Common Stock (DAWN) driven by superior Momentum & Technical, Options & Structure while DSGN counters with relative strength in Growth & Margin. Fundamentally, DSGN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DAWN at N/M Forward P/E and -51.1% operating margin (+83.9% YoY). In options structure, DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro) against DAWN sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DSGN N/M vs DAWN N/M Fwd P/E
Growth & Margin Winner DSGN
Op Margin 0.0% vs -51.1% ยท YoY +0.0% vs +83.9%
Momentum & Technical Winner DAWN
1Y +40.8% vs +201.5% ยท 52W Pos 30% vs 100%
Options & Structure Winner DAWN
BREAKDOWN (13th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
1M Return -3.59%
1Y Return +40.79%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
DAWN NASDAQ
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
1M Return +0.8%
1Y Return +201.54%
Forward P/E N/M
Unified AI Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DSGN +40.79% DAWN +201.54% Spread: +53.9 pp (DAWN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DSGN TTM Op. Margin: 0.0% DAWN TTM Op. Margin: -51.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs DAWN. Trailing 12-month operating profitability (DSGN 0.0% vs DAWN -51.1%) and valuation multiples (DSGN N/M vs DAWN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DSGN (2) vs DAWN (6)
Institutional Metric DSGN DAWN Criterion Row Winner
Market Capitalization Scale $677.5M $2.2B Larger Scale DAWN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +83.9% Higher Growth DAWN
Operating Margin (TTM) Profitability 0.0% -51.1% Higher Margin DSGN
Net Profit Margin Profitability 0.0% -67.8% Higher Margin DSGN
Return on Equity (ROE) Capital Efficiency -36.9% -22.7% Higher ROE DAWN
52-Week Range Position Momentum 30% ($7โ€“$17) 100% ($6โ€“$22) Stronger Trend DAWN
Beta / 30D Volatility Risk Regime 1.32ฮฒ ยท 61% Vol 0.03ฮฒ ยท 2% Vol Lower Realized Risk DAWN
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 58.3 / 100 (HOLD) Higher Composite DAWN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DSGN vs DAWN Buy Guide
DSGN BREAKDOWN
139d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live DSGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DAWN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live DAWN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DSGN nor DAWN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.